Simulations Plus Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Simulations Plus wird ein Gewinn- und Umsatzwachstum von 29.3% bzw. 15% pro Jahr prognostiziert, während der Gewinn pro Aktie um 26.1% pro Jahr wachsen soll.

Wichtige Informationen

29.3%

Wachstumsrate der Gewinne

26.1%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	30.6%
Wachstumsrate der Einnahmen	15.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI

Feb 01

We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit

Jan 12

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Nov 06

Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Sep 06

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Jun 28

Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Feb 10

With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case

Nov 23

A Look At The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Oct 21

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Sep 19

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:SLP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
8/31/2027	120	N/A	27	N/A	1
8/31/2026	102	19	24	31	6
8/31/2025	91	17	18	25	7
8/31/2024	70	10	9	13	N/A
5/31/2024	67	10	10	15	N/A
2/29/2024	65	11	13	18	N/A
11/30/2023	62	11	13	17	N/A
8/31/2023	60	10	18	22	N/A
5/31/2023	56	10	22	27	N/A
2/28/2023	54	10	18	22	N/A
11/30/2022	53	11	15	19	N/A
8/31/2022	54	12	14	18	N/A
5/31/2022	52	12	14	18	N/A
2/28/2022	50	12	14	19	N/A
11/30/2021	48	10	12	17	N/A
8/31/2021	46	10	15	19	N/A
5/31/2021	46	12	12	16	N/A
2/28/2021	46	11	10	14	N/A
11/30/2020	43	10	11	14	N/A
8/31/2020	42	9	8	11	N/A
5/31/2020	40	9	6	9	N/A
2/29/2020	38	9	8	10	N/A
11/30/2019	36	9	10	12	N/A
8/31/2019	34	9	10	12	N/A
5/31/2019	33	8	10	12	N/A
2/28/2019	31	7	9	11	N/A
11/30/2018	30	9	7	9	N/A
8/31/2018	30	9	7	9	N/A
5/31/2018	29	9	N/A	8	N/A
2/28/2018	27	8	N/A	9	N/A
11/30/2017	26	6	N/A	8	N/A
8/31/2017	24	6	N/A	7	N/A
5/31/2017	22	5	N/A	7	N/A
2/28/2017	21	5	N/A	6	N/A
11/30/2016	21	5	N/A	8	N/A
8/31/2016	20	5	N/A	5	N/A
5/31/2016	20	5	N/A	6	N/A
2/29/2016	20	5	N/A	6	N/A
11/30/2015	19	4	N/A	7	N/A
8/31/2015	18	4	N/A	7	N/A
5/31/2015	17	4	N/A	6	N/A
2/28/2015	14	3	N/A	5	N/A
11/30/2014	13	3	N/A	4	N/A
8/31/2014	11	3	N/A	5	N/A
5/31/2014	11	3	N/A	4	N/A
2/28/2014	10	3	N/A	4	N/A
11/30/2013	10	3	N/A	4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SLPDas prognostizierte Gewinnwachstum (29.3% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: SLPDie Erträge des Unternehmens (29.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: SLPEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: SLPDie Einnahmen des Unternehmens (15% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: SLPDie Einnahmen des Unternehmens (15% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SLP in 3 Jahren voraussichtlich hoch sein wird

Simulations Plus Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.5% to US$52.75

Simulations Plus, Inc. Provides Earnings Guidance for Fiscal Year 2025

Consensus EPS estimates fall by 14%

Simulations Plus, Inc. Updates Earnings Guidance for the Fiscal 2024

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 12% to US$60.33

Recent updates

Simulations Plus, Inc. and University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 7.5% to US$52.75

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Simulations Plus, Inc. Provides Earnings Guidance for Fiscal Year 2025

Simulations Plus, Inc. to Report Q4, 2024 Results on Oct 23, 2024

Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings

Simulations Plus, Inc. Announces Executive Changes, Effective August 30, 2024

Simulations Plus: Declining Margins Are A Problem

Now 21% undervalued after recent price drop

Simulations Plus, Inc. Releases the latest version of its quantitative systems toxicology (QST) platform, DILIsym version X

Upcoming dividend of US$0.06 per share

Simulations Plus: Steady Growth, But What About The Margins?

Consensus EPS estimates fall by 14%

Third quarter dividend of US$0.06 announced

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Simulations Plus, Inc. Updates Earnings Guidance for the Fiscal 2024

Now 12% overvalued after recent price rise

Now 21% overvalued after recent price rise

Simulations Plus, Inc. to Report Q3, 2024 Results on Jul 02, 2024

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 12% to US$60.33

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million.

Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software

Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts

lead Independent Director notifies of intention to sell stock

Upcoming dividend of US$0.06 per share

Second quarter dividend of US$0.06 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 43% overvalued after recent price rise

Simulations Plus, Inc. Declares a Cash Dividend, Payable on May 6, 2024

Why We're Not Concerned About Simulations Plus, Inc.'s (NASDAQ:SLP) Share Price

Simulations Plus, Inc. to Report Q2, 2024 Results on Apr 03, 2024

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Now 22% overvalued after recent price rise

Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI

Simulations Plus, Inc. Releases GastroPlus Version 9.9

Upcoming dividend of US$0.06 per share at 0.6% yield

We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

President of PBPK notifies of intention to sell stock

Simulations Plus, Inc., Annual General Meeting, Feb 08, 2024

Simulations Plus, Inc. to Report Q1, 2024 Results on Jan 03, 2024

Simulations Plus, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Price target decreased by 9.1% to US$53.33

Simulations Plus, Inc. Declares Cash Dividend , Payable on November 6, 2023

Simulations Plus, Inc. to Report Q4, 2023 Results on Oct 25, 2023

Simulations Plus Receives New FDA Grant Award

Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Upcoming dividend of US$0.06 per share at 0.5% yield

Simulations Plus, Inc. Releases ADMET Predictor® 11

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Simulations Plus, Inc. Declares Cash Dividend , Payable on August 7, 2023

Co-Founder & Chairman notifies of intention to sell stock

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Simulations Plus, Inc. to Report Q3, 2023 Results on Jul 06, 2023

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Immunetrics, Inc. from LaunchCyte LLC for $23.5 million.

Price target decreased by 12% to US$55.00

Upcoming dividend of US$0.06 per share at 0.5% yield

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options to buy US$1.5m worth of stock.

President notifies of intention to sell stock

Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool

Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Upcoming dividend of US$0.06 per share

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure

First quarter 2023 earnings: EPS and revenues miss analyst expectations